Skip to main content

Research Repository

Advanced Search

Insulin-like peptide 3 (INSL3) as an indicator of leydig cell insufficiency (LCI) in Middle-aged and older men with hypogonadism: reference range and threshold

Anand-Ivell, Ravinder; Heng, Kee; Antonio, Leen; Bartfai, Gyorgy; Casanueva, Felipe F.; Maggi, Mario; O’Neill, Terence W.; Punab, Margus; Rastrelli, Giulia; Slowikowska-Hilczer, Jolanta; Tournoy, Jos; Vanderschueren, Dirk; Wu, Frederick CW.; Huhtaniemi, Ilpo T; Ivell, Richard

Insulin-like peptide 3 (INSL3) as an indicator of leydig cell insufficiency (LCI) in Middle-aged and older men with hypogonadism: reference range and threshold Thumbnail


Authors

Kee Heng

Leen Antonio

Gyorgy Bartfai

Felipe F. Casanueva

Mario Maggi

Terence W. O’Neill

Margus Punab

Giulia Rastrelli

Jolanta Slowikowska-Hilczer

Jos Tournoy

Dirk Vanderschueren

Frederick CW. Wu

Ilpo T Huhtaniemi

Richard Ivell



Abstract

Insulin-like peptide 3 (INSL3) is a circulating biomarker for Leydig cell functional capacity in men, also indicating Leydig Cell Insufficiency (LCI) and potential primary hypogonadism. Using results from large cohort studies we explore sources of biological and technical variance, and establish a reference range for adult men. It is constitutively secreted with little within-individual variation and reflects testicular capacity to produce testosterone. The main INSL3 assays available indicate good concordance with low technical variance; there is no effect of ethnicity. INSL3 declines with age from 35 years at about 15% per decade. Like low calculated free testosterone, and to a lesser extent low total testosterone, reduced INSL3 is significantly associated with increasing age-related morbidity, including lower overall sexual function, reflecting LCI. Consequently, low INSL3 (≤0.4 ng/ml; ca. <2 SD from the population mean) might serve as an additional biochemical marker in the assessment of functional hypogonadism (late-onset hypogonadism, LOH) where testosterone is in the borderline low range. Excluding individuals with low LCI (INSL3 ≤ 0.4 ng/ml) leads to an age-independent (> 35 years) reference range (serum) for INSL3 in the eugonadal population of 0.4 − 2.3 ng/ml, with low INSL3 prospectively identifying individuals at risk of increased future morbidity.

Citation

Anand-Ivell, R., Heng, K., Antonio, L., Bartfai, G., Casanueva, F. F., Maggi, M., O’Neill, T. W., Punab, M., Rastrelli, G., Slowikowska-Hilczer, J., Tournoy, J., Vanderschueren, D., Wu, F. C., Huhtaniemi, I. T., & Ivell, R. (2024). Insulin-like peptide 3 (INSL3) as an indicator of leydig cell insufficiency (LCI) in Middle-aged and older men with hypogonadism: reference range and threshold. Aging Male, 27(1), Article 2346322. https://doi.org/10.1080/13685538.2024.2346322

Journal Article Type Review
Acceptance Date Apr 17, 2024
Online Publication Date Apr 26, 2024
Publication Date 2024
Deposit Date Apr 27, 2024
Publicly Available Date Apr 30, 2024
Journal Aging Male
Print ISSN 1368-5538
Electronic ISSN 1473-0790
Publisher Taylor and Francis
Peer Reviewed Peer Reviewed
Volume 27
Issue 1
Article Number 2346322
DOI https://doi.org/10.1080/13685538.2024.2346322
Keywords Leydig Cells, INSL3, Male, Reference Values, hypogonadism, Aged, Middle Aged, Hypogonadism - blood, Humans, Proteins - analysis, Testosterone - blood, leydig cell, Insulins - blood, Insulin - blood, HPG axis, Biomarkers - blood, Adult
Public URL https://nottingham-repository.worktribe.com/output/34154903
Publisher URL https://www.tandfonline.com/doi/full/10.1080/13685538.2024.2346322
Additional Information Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.; Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=itam20; Received: 2024-02-16; Accepted: 2024-04-17; Published: 2024-04-26

Files





You might also like



Downloadable Citations